

# SMARTWEALTH DOLLAR ASIA PACIFIC FUND

## March 2021

### BLOOMBERG: AZUSWAP IJ

#### Investment Objective

The objective of this fund is to provide maximum long term investment yield.

#### Investment Strategy

To achieve the investment objective, this fund shall be invested 0% - 20% in short-term instruments (such as time deposits and / or money market mutual funds), and 80% - 100% in offshore instruments (through mutual funds).

#### Return Performance

Last 1-year Period	71.43%
Best Month	Apr-20 13.22%
Worst Month	Mar-20 -11.49%

#### Portfolio Breakdown

Mutual Funds - Equities	95.93%
Cash/Deposit	4.07%

#### Top 5 Holding \*

LASERTEC CORP (JP)	5.00%
MAINFREIGHT LTD (NZ)	4.80%
KOH YOUNG TECHNOLOGY INC (KR)	4.60%
ALCHIP TECHNOLOGIES LTD (TW)	3.80%
ASMEDIA TECHNOLOGY INC (TW)	3.20%

#### Top 3 Country Allocation \*

CHINA	23.80%
TAIWAN	19.90%
JAPAN	16.30%

#### Top 3 Sector Allocation \*

IT	40.30%
HEALTHCARE	16.70%
INDUSTRIALS	10.60%

\*Based on previous month Fund Fact Sheet

#### Key Fund Facts


Fund Size (in mio USD)	USD 134.71
Risk Profile	Moderate - Aggressive
Launch Date	22 Oct 2018
Fund Currency	United States Dollar
Pricing Frequency	Daily
Bid-Offer Spread	5.00%
Management Fee	2.00% p.a.
Custodian Bank Name	Bank HSBC Indonesia
Total Unit	83,510,794.9760

<b>Price per Unit</b>	<b>Bid</b>	<b>Offer</b>
(As of Mar 31, 2021)	USD 1.6131	USD 1.6980

Managed by Allianz Global Investor

	1 Month	3 Months	6 Months	1 Year	3 Years	YTD	Since Inception
SmartWealth Dollar Asia Pacific Fund	-3.93%	3.11%	25.27%	71.43%	N/A	3.11%	69.80%
Benchmark*	-1.08%	2.36%	20.58%	51.77%	N/A	2.36%	39.98%

\*MSCI AC Asia Pacific Net Total Return USD Index (MIAP Index)



#### Manager Commentary

The Fund underperformed the benchmark over the month. On a country basis, stock selection in Taiwan and Japan and the overweight to New Zealand were detractors. From a sector perspective, the overweight to Health Care and Information Technology weighed on returns. On a single stock basis, positions in two pharmaceutical companies – a Chinese vaccine producer and Starpharma (Australia health care) helped most. Conversely, several technology companies including RLX Technology Inc (China e-vapor company), Lasertec (Japanese semiconductor equipment supplier) and ASMedia Technology (Taiwanese semiconductor) weighed on the overall result.

During the month, we sold our holdings in an Australian airline and a Chinese chemicals producer. Furthermore, we added Banpu (a Thai commodity company), a Japanese diversified real estate name, and a Chinese advertising company, to the portfolio. At the end of the month, the top holdings were two companies supplying semiconductor equipment Koh Young Technology (Korea) and Lasertec (Japan), as well as Mainfreight, the New Zealand based logistics company. From a regional perspective, the Fund has an overweight exposure to Taiwan and New Zealand, whereas Japan, China and India are underweight positions. At a sector level, the portfolio has overweight positions in Information Technology and Health Care, whilst only holding selective positions in the Financials, Communication Services and Consumer Discretionary sectors.

#### About Allianz Indonesia

PT Asuransi Allianz Life Indonesia was founded in 1996 and is part of Allianz Asia Pacific which has been present in the region since 1910. Allianz Group is a leading insurance company and asset manager in the world with over 129 years of experience and provides a variety of personal and insurance services, companies, ranging from property, life and health insurance to credit insurance and business insurance services globally.

#### Disclaimer:

SmartWealth Dollar Asia Pacific Fund is unit linked fund offered by PT Asuransi Allianz Life Indonesia (Allianz). This fact sheet is prepared by Allianz. The information presented is for informational use only. The performance of the fund is not guaranteed and the value of the units and the income from them may increase or decrease. Past returns and any forecast are not necessarily a guide to future performance. Allianz does not warrant or make any representations regarding the use or the results of the use of the figures generated in terms of their correctness, accuracy, reliability, or otherwise. You are advised to seek your financial consultant before making any investment.